Northern California Medical Associates — Santa Rosa, California

Northern California Medical Associates is a clinical research site located in Santa Rosa, California, United States 95403.

Crixeo Clinical Trials Trust Score: 14/100 (FAILING). This profile has not yet been claimed by the site owner.

Northern California Medical Associates has participated in 4 clinical trials.

Therapeutic areas: Arthritis, Rheumatoid, Chronic Heart Failure, Congestive Heart Failure.

Sponsors: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Cardiovascular Clinical Sciences Inc, Otsuka Pharmaceutical Development & Commercialization, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Santa Rosa

Browse all research sites in California · View every site in Santa Rosa

Sponsor Feasibility Report

Trust Score: 14/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Northern California Medical Associates?

Northern California Medical Associates has a Crixeo Trust Score of 14/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Northern California Medical Associates conducted?

Northern California Medical Associates has 4 clinical trials on record. Their work covers Arthritis, Rheumatoid, Chronic Heart Failure, Congestive Heart Failure.

Is Northern California Medical Associates accredited by Crixeo Clinical Trials?

Northern California Medical Associates has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Northern California Medical Associates?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.